Skip to content

Prostate cancer in transgender women

The prostate stays after surgery. The risk on hormone therapy, the lower PSA and screening.

Dr. Petronio Melo, urologistA reference in prostate cancer
CRM-SP 157.598 · RQE 70.275
Reviewed by Dr. Petronio Melo on November 13, 2026
Book a consultation
Side-view drawing of the pelvis after vaginoplasty, with the bladder, the prostate in place, the short urethra opening at the perineum and the neovagina between the prostate and the rectum
On this page

Quick answer

Transgender women have a prostate, even after vaginoplasty, so they can develop prostate cancer.2 On hormone therapy, the risk found in studies is much lower than in cisgender men, but the evidence is still weak.1 Estrogen makes PSA much lower, and the usual 4 ng/mL cutoff is probably too high.3 There is no specific guideline for this group, and the decision to screen is individual.1,6

The prostate stays in place

Gender-affirming hormone therapy in transgender women usually combines a medicine that blocks testosterone with estrogen. Surgery removes the testicles and, in most cases, creates the neovagina. The prostate is not removed, because that would carry a risk of complications such as urinary incontinence.2

In the opening drawing, the neovagina lies between the prostate and the rectum, and the shorter urethra opens at the perineum. Since the prostate remains in the body, the risk of prostate cancer remains too.2

Cisgender women do not have a prostate like a man's. Near the opening of the urethra, they have Skene's glands, which some authors call the female prostate. Their structure is similar to the prostate's, and they are the main source of PSA in women, in very small amounts. Cancer in these glands is very rare, with few cases described, all in older women.10

Risk with and without hormones

Without hormone therapy, the risk is the same as in cisgender men. This applies to transgender women who do not use hormones and to non-binary people with a prostate.6

On hormone therapy, the risk found was lower:

  • In the Netherlands, a study followed 2,281 transgender women on hormone therapy for a median of 14 years. There were 6 cases of prostate cancer, a risk about 80% lower than expected for men of the same age.2
  • A 2026 review pooled 9 studies, with 54,342 transgender women on hormone therapy and 160 cases. The risk was about 78% lower than in cisgender men: 22.9 versus 98.1 cases per 100,000 people per year.1

The review authors rated the certainty of this evidence as very low and point out that a lower risk in the population does not mean protection for each person.1 Part of the difference may come from less testing: transgender women aged 55 to 69 had PSA tests less often than cisgender men (22.2% versus 36.3%), and the gap disappeared once the analysis took into account whether a doctor had recommended the test.5

In US veterans' hospitals, between 2000 and 2022, 155 cases of prostate cancer were confirmed in transgender women. Of these, 116 had never used estrogen, 17 had stopped before diagnosis and 22 were using it at diagnosis.4

A family history of prostate cancer raised the risk in transgender women as well.8

PSA is lower on estrogen

PSA depends on testosterone, so it falls sharply on hormone therapy. In a study of 210 transgender women aged 40 or older, taking estrogen and without prostate cancer:3

  • The median PSA was 0.02 ng/mL, about 50 times lower than in cisgender men of the same age.
  • 95% had a PSA up to 0.6 ng/mL.
  • In 36%, PSA was undetectable: 49% of those who had their testicles removed and 23% of those who had not.

That is why the 4 ng/mL cutoff, defined in cisgender men, is probably too high for people taking estrogen. There is still no validated cutoff for this group.1,3

Is the disease more severe?

This is not yet known. A study that compared 199 transgender women and 995 cisgender men with prostate cancer and a similar profile found no clear difference in metastasis at diagnosis, high-risk disease or death from the cancer. However, the study was too small to detect moderate differences.7

Other data call for attention. In the 2026 review, one third of the cases with a reported grade were high grade (ISUP 4 or 5), but these data came from fewer than 40 patients.1 In a US database, hormone therapy was linked to less prostate cancer but, among those who already had the disease, to more PSA recurrence and more bone metastasis.8 These are observational studies, which do not prove cause.

Screening

No guideline has a specific recommendation for transgender women.1,6 The 2026 review calls for validated PSA values and screening pathways for this group.1

Until then, the decision to test is made through a conversation, as I explain in prostate cancer screening, taking into account age, family history, hormone use and any surgery.6 People who do not use hormones have the same risk as cisgender men, and the conversation is the same.6

Treatment

Treatment of prostate cancer in transgender women is individualized and, when possible, includes the input of the surgeon who did the reconstruction. Both surgery and radiotherapy can have a large effect on quality of life, and that is part of the decision.9

The consultation

The consultation can be in person, in São Paulo, or online. It helps to bring previous PSA results, the list of hormones you take and information about any surgery you have had.

When to see a urologist

  • If you are unsure whether to have prostate screening
  • If your PSA has gone up, even within what the report calls normal
  • If there are cases of prostate cancer in your family
  • If you have difficulty urinating or blood in your urine
  • If you have stopped hormone therapy or have never used hormones

Frequently asked questions

Do transgender women have a prostate?

Yes. Gender-affirming surgery removes the testicles and creates the neovagina, but the prostate stays in place, because removing it would carry a risk of complications such as urinary incontinence. That is why the risk of prostate cancer remains.2

Do women have a prostate?

Cisgender women do not have a prostate like a man's. Near the opening of the urethra, they have Skene's glands, which some authors call the female prostate: their structure is similar to the prostate's, and they are the main source of PSA in women. Cancer in these glands is very rare.10 Transgender women, on the other hand, do have a prostate, even after surgery.2

Does hormone therapy lower the risk of prostate cancer?

In studies, yes. A 2026 review of more than 54,000 transgender women on hormone therapy found a risk about 78% lower than in cisgender men of the same age. But the certainty of this evidence is very low, and a lower risk in the population does not mean protection for each person.1

Is PSA different in a transgender woman taking estrogen?

It is much lower. In a study of 210 transgender women aged 40 or older taking estrogen, the median PSA was 0.02 ng/mL, and 95% had values up to 0.6 ng/mL. The 4 ng/mL cutoff, designed for cisgender men, is probably too high in this group.3

Should transgender women have prostate screening?

There is no specific guideline for transgender women. The decision to screen comes from an individual conversation that takes into account age, family history, hormone use and any surgery.1,6

Is prostate cancer more aggressive in transgender women?

This is not yet known. In a study that compared transgender women and cisgender men with similar profiles, there was no clear difference in metastasis or high-risk disease, but the study was too small to detect moderate differences.7

References

  1. Oberoi K, Trevaskis I, Hassan S, et al. Prostate Cancer Incidence and Disease Characteristics in Transgender Women Receiving Gender-affirming Hormone Therapy: A Systematic Review with Meta-analysis. Eur Urol Oncol. 2026. doi:10.1016/j.euo.2026.10.002 PubMed
  2. de Nie I, de Blok CJM, van der Sluis TM, et al. Prostate Cancer Incidence under Androgen Deprivation: Nationwide Cohort Study in Trans Women Receiving Hormone Treatment. J Clin Endocrinol Metab. 2020;105(9):e3293-e3299. PubMed
  3. Nik-Ahd F, De Hoedt AM, Butler C, et al. Prostate-Specific Antigen Values in Transgender Women Receiving Estrogen. JAMA. 2024;332(4):335-337. PubMed
  4. Nik-Ahd F, De Hoedt A, Butler C, et al. Prostate Cancer in Transgender Women in the Veterans Affairs Health System, 2000-2022. JAMA. 2023;329(21):1877-1879. PubMed
  5. Kalavacherla S, Riviere P, Kalavacherla S, et al. Prostate Cancer Screening Uptake in Transgender Women. JAMA Netw Open. 2024;7(2):e2356088. PubMed
  6. Bertoncelli Tanaka M, Sahota K, Burn J, et al. Prostate cancer in transgender women: what does a urologist need to know? BJU Int. 2022;129(1):113-122. PubMed
  7. Meagher M, Morgan K, Deshler L, et al. Prostate cancer in transgender women: A propensity score-matched analysis of disease severity and survival. Cancer. 2024;130(22):3863-3869. PubMed
  8. Manfredi C, Franco A, Ditonno F, et al. Prevalence and Factors Associated With Prostate Cancer Among Transgender Women. JAMA Oncol. 2024;10(12):1697-1700. PubMed
  9. Crowley F, Mihalopoulos M, Gaglani S, et al. Prostate cancer in transgender women: considerations for screening, diagnosis and management. Br J Cancer. 2023;128(2):177-189. PubMed
  10. Garaz R, Stenzl A, Singer S, Mattern S, Bedke J, Amend B. Female Hyperplastic PSA-Positive Prostate Tissue in the Bladder Neck. Urol Int. 2024;108(2):163-167. PubMed

Would you like to talk about your case?

In the consultation, I go over your tests and your priorities.

Book a consultation

Related guides